Hepatopancreatobiliary manifestations of inflammatory bowel disease

Kazuhiko Nakamura, Tetsuhide Ito, Kazuhiro Kotoh, Eikichi Ihara, Haruei Ogino, tsutomu iwasa, Yoshimasa Tanaka, Yoichiro Iboshi, Ryoichi Takayanagi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations such as hepatopancreatobiliary manifestations (HPBMs), which include primary sclerosing cholangitis (PSC), pancreatitis, and cholelithiasis. PSC is correlated with IBD, particularly ulcerative colitis (UC); 70-80% of PSC patients in Western countries and 20-30% in Japan have comorbid UC. Therefore, patients diagnosed with PSC should be screened for UC by total colonoscopy. While symptoms of PSC-associated UC are usually milder than PSC-negative UC, these patients have a higher risk of colorectal cancer, particularly in the proximal colon. Therefore, regular colonoscopy surveillance is required regardless of UC symptoms. Administration of 5-aminosalicylic acid or ursodeoxycholic acid may prevent colorectal cancer and cholangiocarcinoma. While PSC is diagnosed by diffuse multifocal strictures on cholangiography, it must be carefully differentiated from immunoglobulin G4 (IgG4)-associated cholangitis, which shows a similar cholangiogram but requires different treatment. When PSC is suspected despite a normal cholangiogram, the patient may have small-duct PSC, which requires a liver biopsy. IBD patients have a high incidence of acute and chronic pancreatitis. Most cases are induced by cholelithiasis or medication, although some patients may have autoimmune pancreatitis (AIP), most commonly type 2 without elevation of serum IgG4. AIP should be accurately identified based on characteristic image findings, because AIP responds well to corticosteroids. Crohn's disease is frequently associated with gallstones, and several risk factors are indicated. HPBMs may influence the management of IBD, therefore, accurate diagnosis and an appropriate therapeutic strategy are important, as treatment depends upon the type of HPBM.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalClinical Journal of Gastroenterology
Volume5
Issue number1
DOIs
Publication statusPublished - Feb 1 2012

Fingerprint

Sclerosing Cholangitis
Inflammatory Bowel Diseases
Ulcerative Colitis
Pancreatitis
Cholelithiasis
Colonoscopy
Immunoglobulins
Colorectal Neoplasms
Mesalamine
Ursodeoxycholic Acid
Cholangitis
Cholangiocarcinoma
Cholangiography
Chronic Pancreatitis
Gallstones
Crohn Disease
Japan
Adrenal Cortex Hormones
Pathologic Constriction
Colon

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Hepatopancreatobiliary manifestations of inflammatory bowel disease. / Nakamura, Kazuhiko; Ito, Tetsuhide; Kotoh, Kazuhiro; Ihara, Eikichi; Ogino, Haruei; iwasa, tsutomu; Tanaka, Yoshimasa; Iboshi, Yoichiro; Takayanagi, Ryoichi.

In: Clinical Journal of Gastroenterology, Vol. 5, No. 1, 01.02.2012, p. 1-8.

Research output: Contribution to journalReview article

Nakamura, K, Ito, T, Kotoh, K, Ihara, E, Ogino, H, iwasa, T, Tanaka, Y, Iboshi, Y & Takayanagi, R 2012, 'Hepatopancreatobiliary manifestations of inflammatory bowel disease', Clinical Journal of Gastroenterology, vol. 5, no. 1, pp. 1-8. https://doi.org/10.1007/s12328-011-0282-1
Nakamura, Kazuhiko ; Ito, Tetsuhide ; Kotoh, Kazuhiro ; Ihara, Eikichi ; Ogino, Haruei ; iwasa, tsutomu ; Tanaka, Yoshimasa ; Iboshi, Yoichiro ; Takayanagi, Ryoichi. / Hepatopancreatobiliary manifestations of inflammatory bowel disease. In: Clinical Journal of Gastroenterology. 2012 ; Vol. 5, No. 1. pp. 1-8.
@article{675fcfbb78e34ad3803fc323a8c03518,
title = "Hepatopancreatobiliary manifestations of inflammatory bowel disease",
abstract = "Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations such as hepatopancreatobiliary manifestations (HPBMs), which include primary sclerosing cholangitis (PSC), pancreatitis, and cholelithiasis. PSC is correlated with IBD, particularly ulcerative colitis (UC); 70-80{\%} of PSC patients in Western countries and 20-30{\%} in Japan have comorbid UC. Therefore, patients diagnosed with PSC should be screened for UC by total colonoscopy. While symptoms of PSC-associated UC are usually milder than PSC-negative UC, these patients have a higher risk of colorectal cancer, particularly in the proximal colon. Therefore, regular colonoscopy surveillance is required regardless of UC symptoms. Administration of 5-aminosalicylic acid or ursodeoxycholic acid may prevent colorectal cancer and cholangiocarcinoma. While PSC is diagnosed by diffuse multifocal strictures on cholangiography, it must be carefully differentiated from immunoglobulin G4 (IgG4)-associated cholangitis, which shows a similar cholangiogram but requires different treatment. When PSC is suspected despite a normal cholangiogram, the patient may have small-duct PSC, which requires a liver biopsy. IBD patients have a high incidence of acute and chronic pancreatitis. Most cases are induced by cholelithiasis or medication, although some patients may have autoimmune pancreatitis (AIP), most commonly type 2 without elevation of serum IgG4. AIP should be accurately identified based on characteristic image findings, because AIP responds well to corticosteroids. Crohn's disease is frequently associated with gallstones, and several risk factors are indicated. HPBMs may influence the management of IBD, therefore, accurate diagnosis and an appropriate therapeutic strategy are important, as treatment depends upon the type of HPBM.",
author = "Kazuhiko Nakamura and Tetsuhide Ito and Kazuhiro Kotoh and Eikichi Ihara and Haruei Ogino and tsutomu iwasa and Yoshimasa Tanaka and Yoichiro Iboshi and Ryoichi Takayanagi",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s12328-011-0282-1",
language = "English",
volume = "5",
pages = "1--8",
journal = "Clinical Journal of Gastroenterology",
issn = "1865-7257",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Hepatopancreatobiliary manifestations of inflammatory bowel disease

AU - Nakamura, Kazuhiko

AU - Ito, Tetsuhide

AU - Kotoh, Kazuhiro

AU - Ihara, Eikichi

AU - Ogino, Haruei

AU - iwasa, tsutomu

AU - Tanaka, Yoshimasa

AU - Iboshi, Yoichiro

AU - Takayanagi, Ryoichi

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations such as hepatopancreatobiliary manifestations (HPBMs), which include primary sclerosing cholangitis (PSC), pancreatitis, and cholelithiasis. PSC is correlated with IBD, particularly ulcerative colitis (UC); 70-80% of PSC patients in Western countries and 20-30% in Japan have comorbid UC. Therefore, patients diagnosed with PSC should be screened for UC by total colonoscopy. While symptoms of PSC-associated UC are usually milder than PSC-negative UC, these patients have a higher risk of colorectal cancer, particularly in the proximal colon. Therefore, regular colonoscopy surveillance is required regardless of UC symptoms. Administration of 5-aminosalicylic acid or ursodeoxycholic acid may prevent colorectal cancer and cholangiocarcinoma. While PSC is diagnosed by diffuse multifocal strictures on cholangiography, it must be carefully differentiated from immunoglobulin G4 (IgG4)-associated cholangitis, which shows a similar cholangiogram but requires different treatment. When PSC is suspected despite a normal cholangiogram, the patient may have small-duct PSC, which requires a liver biopsy. IBD patients have a high incidence of acute and chronic pancreatitis. Most cases are induced by cholelithiasis or medication, although some patients may have autoimmune pancreatitis (AIP), most commonly type 2 without elevation of serum IgG4. AIP should be accurately identified based on characteristic image findings, because AIP responds well to corticosteroids. Crohn's disease is frequently associated with gallstones, and several risk factors are indicated. HPBMs may influence the management of IBD, therefore, accurate diagnosis and an appropriate therapeutic strategy are important, as treatment depends upon the type of HPBM.

AB - Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations such as hepatopancreatobiliary manifestations (HPBMs), which include primary sclerosing cholangitis (PSC), pancreatitis, and cholelithiasis. PSC is correlated with IBD, particularly ulcerative colitis (UC); 70-80% of PSC patients in Western countries and 20-30% in Japan have comorbid UC. Therefore, patients diagnosed with PSC should be screened for UC by total colonoscopy. While symptoms of PSC-associated UC are usually milder than PSC-negative UC, these patients have a higher risk of colorectal cancer, particularly in the proximal colon. Therefore, regular colonoscopy surveillance is required regardless of UC symptoms. Administration of 5-aminosalicylic acid or ursodeoxycholic acid may prevent colorectal cancer and cholangiocarcinoma. While PSC is diagnosed by diffuse multifocal strictures on cholangiography, it must be carefully differentiated from immunoglobulin G4 (IgG4)-associated cholangitis, which shows a similar cholangiogram but requires different treatment. When PSC is suspected despite a normal cholangiogram, the patient may have small-duct PSC, which requires a liver biopsy. IBD patients have a high incidence of acute and chronic pancreatitis. Most cases are induced by cholelithiasis or medication, although some patients may have autoimmune pancreatitis (AIP), most commonly type 2 without elevation of serum IgG4. AIP should be accurately identified based on characteristic image findings, because AIP responds well to corticosteroids. Crohn's disease is frequently associated with gallstones, and several risk factors are indicated. HPBMs may influence the management of IBD, therefore, accurate diagnosis and an appropriate therapeutic strategy are important, as treatment depends upon the type of HPBM.

UR - http://www.scopus.com/inward/record.url?scp=84857782507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857782507&partnerID=8YFLogxK

U2 - 10.1007/s12328-011-0282-1

DO - 10.1007/s12328-011-0282-1

M3 - Review article

AN - SCOPUS:84857782507

VL - 5

SP - 1

EP - 8

JO - Clinical Journal of Gastroenterology

JF - Clinical Journal of Gastroenterology

SN - 1865-7257

IS - 1

ER -